ALDX Aldeyra Therapeutics Inc.

5.34
+0.02  (+0%)
Previous Close 5.32
Open 5.44
Price To Book 2.93
Market Cap 149,271,479
Shares 27,952,937
Volume 37,911
Short Ratio
Av. Daily Volume 310,979
Stock charts supplied by TradingView

NewsSee all news

  1. Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

    Primary objective of RENEW Part 1 achieved: Induction-maintenance dosing regimen of topical ocular reproxalap advanced to RENEW Part 2 Reproxalap statistically superior to vehicle in RENEW co-primary endpoint of

  2. Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

    Event scheduled for 8:00 a.m. ET Tuesday, December 3, 2019 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Tuesday, December 3, 2019, to provide top-line

  3. Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today

  4. Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

    Part I of Adaptive RENEW Phase 3 Clinical Trial in Dry Eye Disease on Track for Completion in Fourth Quarter 2019 Adaptive GUARD Phase 3 Clinical Trial of ADX-2191 in Proliferative Vitreoretinopathy to Initiate in

  5. Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Part 2 to be initiated 1H 2020.
ADX-102 - topical ocular reproxalap - RENEW
Dry eye syndrome
Phase 3 trial to be initiated 1H 2020.
Reproxalap (ADX-102) - INVIGORATE
Allergic conjunctivitis
Phase 3 data did not meet endpoints - June 25, 2019.
ADX-102 reproxalap
Noninfectious anterior uveitis
Phase 3 Part 1 section of trial completed.
Reproxalap (ADX-102)
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated 4Q 2019.
ADX-1612 (ganetespib)
Post-transplant lymphoproliferative disorder
Phase 3 trial to be initiated 4Q 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)

Latest News

  1. Aldeyra Therapeutics Announces Positive Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

    Primary objective of RENEW Part 1 achieved: Induction-maintenance dosing regimen of topical ocular reproxalap advanced to RENEW Part 2 Reproxalap statistically superior to vehicle in RENEW co-primary endpoint of

  2. Aldeyra Therapeutics to Host Conference Call and Webcast to Announce Top-Line Results from Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease

    Event scheduled for 8:00 a.m. ET Tuesday, December 3, 2019 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Tuesday, December 3, 2019, to provide top-line

  3. Aldeyra Therapeutics to Present at Upcoming Healthcare Investor Conferences

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today

  4. Aldeyra Therapeutics Reports Third-Quarter 2019 Financial Results and Provides Updates on Anticipated Clinical Milestones

    Part I of Adaptive RENEW Phase 3 Clinical Trial in Dry Eye Disease on Track for Completion in Fourth Quarter 2019 Adaptive GUARD Phase 3 Clinical Trial of ADX-2191 in Proliferative Vitreoretinopathy to Initiate in

  5. Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third-Quarter 2019 Financial Results and Corporate Update

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today

  6. Aldeyra Therapeutics Releases Expanded Results from Allergen Chamber Trial and Announces Plans to Initiate the Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

    Highly statistically significant activity relative to vehicle across every assessed symptom and sign observed in allergen chamber clinical trial Agreement reached with U.S. FDA on design of Phase 3 INVIGORATE trial,

  7. Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis

    Event scheduled for 8:00 a.m. ET Thursday, October 31, 2019 Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded

  8. Aldeyra Therapeutics to Present at Ophthalmology Innovation Summit at American Academy of Ophthalmology 2019 Annual Meeting

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present on Thursday, October 10 at the Ophthalmology Innovation Summit (OIS) at the

  9. Aldeyra Therapeutics to Present Phase 3 ALLEVIATE Trial Results in Allergic Conjunctivitis at American Academy of Ophthalmology 2019 Annual Meeting

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced that it will host an ePoster presentation and discussion of the company's ALLEVIATE Phase 3 clinical trial of reproxalap in patients with allergic

  10. Aldeyra Therapeutics to Present at 2019 Cantor Global Healthcare Conference

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today